Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
latest_posts
- 1
6 Famous Urban communities for Shopping on the planet - 2Can scientists detect life without knowing what it looks like? Research using machine learning offers a new way
- 3First foreign troop in new gang suppression force lands in Haiti to replace previous mission
- 4Hubble Space Telescope spies dusty debris from two cosmic collisions
- 5What's changing about healthcare in 2026 — Medicare, Medicaid, ACA, premiums, and enrollment deadlines
- 5 VIPs That Changed Style
- Putting resources into Yourself: Self-awareness Techniques
- These Cities Led Global Jet-Setting In 2025, According To New Data
- Make your choice for a definitive Christmas getaway destination!
- Find the Specialty of Calligraphy: Dominating the Exquisite Art of Penmanship
- More parents refusing vitamin K shots for newborns, study finds
- From Loner to Force to be reckoned with: Individual Accounts of Change
- Remain Fit: Powerful Wellness and Work-out Schedules for a Better You
- Cyber Monday 2025 streaming deal: Get $42 off six months of Apple TV
